PATRYS Ltd (PAB) - Cash Flow Conversion Efficiency

Latest as of June 2025: -2.365x

Based on the latest financial reports, PATRYS Ltd (PAB) has a cash flow conversion efficiency ratio of -2.365x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.73 Million ≈ $-1.23 Million USD) by net assets (AU$732.87K ≈ $518.56K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See PATRYS Ltd balance sheet independence to measure how much of total assets are equity-financed.

PATRYS Ltd - Cash Flow Conversion Efficiency Trend (2008–2025)

This chart illustrates how PATRYS Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check PAB operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.

PATRYS Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of PATRYS Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
PYRAMID AG NA KONV.
XETRA:M3B0
0.092x
Hunting PLC
LSE:HTG
0.046x
Irisity AB
ST:IRIS
-0.017x
Mason Graphite Inc.
V:LLG
-0.007x
Watta Holding Bhd
KLSE:7226
-0.009x
Touchwood Entertainment Limited
NSE:TOUCHWOOD
-0.092x
Robogroup
TA:ROBO
-0.260x
Kentima Holding publ AB
ST:KENH
0.127x

Annual Cash Flow Conversion Efficiency for PATRYS Ltd (2008–2025)

The table below shows the annual cash flow conversion efficiency of PATRYS Ltd from 2008 to 2025. For the full company profile with market capitalisation and key ratios, see PATRYS Ltd market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-06-30 AU$732.87K
≈ $518.56K
AU$-1.77 Million
≈ $-1.26 Million
-2.421x -362.62%
2024-06-30 AU$3.47 Million
≈ $2.46 Million
AU$-1.82 Million
≈ $-1.28 Million
-0.523x +38.08%
2023-06-30 AU$6.84 Million
≈ $4.84 Million
AU$-5.78 Million
≈ $-4.09 Million
-0.845x -30.75%
2022-06-30 AU$13.43 Million
≈ $9.50 Million
AU$-8.68 Million
≈ $-6.14 Million
-0.646x -100.76%
2021-06-30 AU$12.04 Million
≈ $8.52 Million
AU$-3.88 Million
≈ $-2.74 Million
-0.322x +37.06%
2020-06-30 AU$4.88 Million
≈ $3.45 Million
AU$-2.50 Million
≈ $-1.77 Million
-0.512x -2789.46%
2019-06-30 AU$7.30 Million
≈ $5.16 Million
AU$-129.19K
≈ $-91.41K
-0.018x +93.81%
2018-06-30 AU$7.29 Million
≈ $5.16 Million
AU$-2.09 Million
≈ $-1.48 Million
-0.286x +40.32%
2017-06-30 AU$2.66 Million
≈ $1.88 Million
AU$-1.28 Million
≈ $-903.55K
-0.480x -13.93%
2016-06-30 AU$3.64 Million
≈ $2.57 Million
AU$-1.53 Million
≈ $-1.08 Million
-0.421x +59.39%
2015-06-30 AU$3.97 Million
≈ $2.81 Million
AU$-4.11 Million
≈ $-2.91 Million
-1.036x -153.21%
2014-06-30 AU$12.43 Million
≈ $8.80 Million
AU$-5.09 Million
≈ $-3.60 Million
-0.409x -67.78%
2013-06-30 AU$10.77 Million
≈ $7.62 Million
AU$-2.63 Million
≈ $-1.86 Million
-0.244x +19.13%
2012-06-30 AU$12.45 Million
≈ $8.81 Million
AU$-3.75 Million
≈ $-2.66 Million
-0.302x +20.56%
2011-06-30 AU$13.47 Million
≈ $9.53 Million
AU$-5.11 Million
≈ $-3.62 Million
-0.380x +18.00%
2010-06-30 AU$15.23 Million
≈ $10.78 Million
AU$-7.05 Million
≈ $-4.99 Million
-0.463x -13.05%
2009-06-30 AU$17.72 Million
≈ $12.54 Million
AU$-7.26 Million
≈ $-5.14 Million
-0.410x -26.26%
2008-06-30 AU$22.98 Million
≈ $16.26 Million
AU$-7.45 Million
≈ $-5.27 Million
-0.324x --

About PATRYS Ltd

AU:PAB Australia
Market Cap
$7.96 Million
AU$11.24 Million AUD
Market Cap Rank
#27598 Global
#1369 in Australia
Share Price
AU$0.03
Change (1 day)
+0.00%
52-Week Range
AU$0.00 - AU$0.05
All Time High
AU$0.07
About

Patrys Limited, together with its subsidiaries, develops antibody technologies for the treatment of cancer and NETosis-driven inflammatory diseases. It develops PAT-DX1, a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10; and PAT-DX3 for treating primary and secondary brain cancers, and metastases that are associated wit… Read more